Efficacy and Safety Investigation of NNC0194-0499 Co-administered With Semaglutide in Subjects With Non-alcoholic Steatohepatitis: a Dose-ranging, Placebo Controlled Trial
Latest Information Update: 30 Sep 2024
At a glance
- Drugs NNC0194 0499 (Primary) ; Semaglutide (Primary) ; Cagrilintide
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 06 Aug 2024 Planned primary completion date changed from 29 Oct 2024 to 31 Oct 2024.
- 10 Jun 2024 Planned primary completion date changed from 8 May 2024 to 29 Oct 2024.
- 29 Dec 2023 Planned End Date changed from 27 Dec 2024 to 12 Mar 2025.